SEC Form 4 · accession 0000899243-18-019753
Wave Life Sciences, Inc. · WVE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Chris Francis
Officer — See Remarks
Period of report
Jul 9, 2018
Accepted (ET)
Jul 11, 2018 · 5:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631574
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Jul 9, 2018 | M | 23,900 | $2.48 | A | 45,977 | D | |
| Ordinary SharesF2 | Jul 9, 2018 | S | 23,900 | $37.25 | D | 22,077 | D | |
| Ordinary Shares | Jul 9, 2018 | M | 596 | $2.48 | A | 22,673 | D | |
| Ordinary SharesF3 | Jul 9, 2018 | S | 596 | $38.22 | D | 22,077 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (right to buy)F4 | $2.48 | Jul 9, 2018 | M | 24,496 | D | — | Mar 10, 2025 | Ordinary Shares | 24,496 | 52,572 | D |
Explanation of responses
- F1The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018.
- F2The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $37.00 to $37.975 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- F3The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $38.10 to $38.25 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- F4The share option represented a right to purchase a total of 126,174 ordinary shares, 25% of which became exercisable on April 15, 2015, and the remaining shares vest in 36 equal monthly installments thereafter.
Remarks
SVP, Corporate Development, Head of Emerging Areas